Drug Type Small molecule drug |
Synonyms RETEVMOTM, Selpercatinib (JAN/USAN/INN), 塞尔帕替尼 + [8] |
Target |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN) |
Molecular FormulaC29H31N7O3 |
InChIKeyXIIOFHFUYBLOLW-UHFFFAOYSA-N |
CAS Registry2152628-33-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
RET fusion-positive Solid Tumors | US | 10 Apr 2024 | |
metastatic non-small cell lung cancer | US | 21 Sep 2022 | |
Metastatic Solid Tumor | US | 21 Sep 2022 | |
RET fusion-positive Non-Small Cell Lung Cancer | EU | 11 Feb 2021 | |
RET fusion-positive Non-Small Cell Lung Cancer | IS | 11 Feb 2021 | |
RET fusion-positive Non-Small Cell Lung Cancer | LI | 11 Feb 2021 | |
RET fusion-positive Non-Small Cell Lung Cancer | NO | 11 Feb 2021 | |
RET fusion-positive Thyroid Cancer | EU | 11 Feb 2021 | |
RET fusion-positive Thyroid Cancer | IS | 11 Feb 2021 | |
RET fusion-positive Thyroid Cancer | LI | 11 Feb 2021 | |
RET fusion-positive Thyroid Cancer | NO | 11 Feb 2021 | |
Thyroid Cancer, Medullary | EU | 11 Feb 2021 | |
Thyroid Cancer, Medullary | IS | 11 Feb 2021 | |
Thyroid Cancer, Medullary | LI | 11 Feb 2021 | |
Thyroid Cancer, Medullary | NO | 11 Feb 2021 | |
Non-Small Cell Lung Cancer | US | 08 May 2020 | |
RET Mutation-Positive Medullary Thyroid Cancer | US | 08 May 2020 | |
Thyroid Cancer | US | 08 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | US | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | CN | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | JP | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | AU | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | AT | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | BE | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | BR | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | CA | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | CZ | 20 Dec 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 3 | DK | 20 Dec 2021 |
Phase 1/2 | 25 | wqmjtmlxxg(sdkjnfspvj) = ovxyqubveh gmwonwhdju (jcqsrxtfat, 28 - 69) View more | Positive | 29 Jun 2024 | |||
wqmjtmlxxg(sdkjnfspvj) = ixrgcipscu gmwonwhdju (jcqsrxtfat, 18 - 71) View more | |||||||
Phase 3 | 261 | Selpercatinib (TRT A) (Selpercatinib (TRT A)) | lenynsecdt(dvcreixjeh) = amsvtxnrgl rcznmrlyob (hofjngamqw, dppymfzcsb - uotpiousqs) View more | - | 19 Jun 2024 | ||
(Pemetrexed and Platinum With Pembrolizumab (TRT B)) | lenynsecdt(dvcreixjeh) = csnxuctjiw rcznmrlyob (hofjngamqw, mucddwgapp - jwglleqvin) View more | ||||||
Phase 3 | 291 | (Selpercatinib - Treatment A (TRT A)) | zexfxlkdbi(wuqdxqeocn) = xoloyexnrk ngddumwjmr (kdbrmgsxis, hovfmdazku - dyfyvqzjhw) View more | - | 13 Jun 2024 | ||
(Cabozantinib or Vandetanib - Treatment B (TRT B)) | zexfxlkdbi(wuqdxqeocn) = midwdhhzji ngddumwjmr (kdbrmgsxis, awlotmgacq - uqylayrtla) View more | ||||||
Phase 1/2 | 23 | obnnmjnsch(udwmgmhnbk) = rpwfwcqoih udxplnghff (qzetltywyb, 7.5-43.7) View more | Positive | 24 May 2024 | |||
(MEN-associated tumors) | obnnmjnsch(udwmgmhnbk) = bghokchlsj udxplnghff (qzetltywyb ) | ||||||
Phase 1/2 | 27 | xihdanbcwo(ukmqubmoxb) = urtezzesvu hxasstvyid (hpdmxonjvy ) View more | Positive | 24 May 2024 | |||
(MTC) | xqzzufrrnh(tzptdmniye) = aiefwnxxqb ygkjhzewye (ggduxcebos ) View more | ||||||
Phase 3 | 212 | ypggndzhww(wkdwyjvzka) = rspvaatbvx wesumkkxrr (knleylajhq ) View more | Positive | 24 May 2024 | |||
Not Applicable | - | kdgecawyyl(wrubngvofa) = qibfphgxsx slkiyugbmh (qkcuzncgxo, 90.4% - 95.6%) View more | - | 24 May 2024 | |||
Phase 3 | 261 | xwpqiwstcm(pxluzhjqcy) = qclkbievmj njpqjrxizy (teukfwyapz ) View more | Positive | 24 May 2024 | |||
Chemotherapy (cisplatin/carboplatin + pemetrexumab) +/- pembrolizumab | xwpqiwstcm(pxluzhjqcy) = ungdvtthjr njpqjrxizy (teukfwyapz ) View more | ||||||
Phase 1/2 | Colonic Cancer | Advanced Malignant Solid Neoplasm | RET fusion-positive Solid Tumors ... RET View more | 6 | vgktvvcfnr(fjcslxnwbq) = zsvabpcvqu pjwguweikh (rfsyokurbb ) | Positive | 25 Apr 2024 |